13% sales growth driven by Victoza®, NovoRapid® and Levemir®
1 May - "We are pleased with the strong sales in the first quarter of 2013 driven by our portfolio of modern insulins and Victoza®. We have launched Tresiba®, the new-generation insulin with an ultra-long duration of action, in a number of countries and are encouraged by the early feedback from patients and doctors", says Lars Rebien Sørensen, president and CEO.
World Haemophilia Day in Myanmar
17 April - In Myanmar, an estimated 5,400 people have haemophilia - only about 150 are diagnosed. Together with the Novo Nordisk Haemophilia Foundation (NNHF), Novo Nordisk is conducting a global fundraiser to support people with haemophilia in Myanmar. Susanne Brandl, general manager of the NNHF, explains: “In most countries there is some kind of organisation to support people with haemophilia, but in Myanmar there is no such thing, so we start by establishing a patient organisation, and then we rely on the raised funds to make the association active as quickly as possible. By doing this, we believe that we can definitely make a difference.” Read more about the Haemophilia Foundation and See the facts about Haemophilia in graphics (pdf)
Novo Nordisk celebrates 90th anniversary
11 March - It is 90 years ago since the first diabetes patients were treated with insulin from Novo Nordisk. Ever since, the company has been focused on developing new and better treatments for people with diabetes and is today the world’s largest diabetes care company. Novo Nordisk provides therapeutic treatments for an estimated 23 million people with diabetes worldwide, and produces approximately 50% of all insulin in the world.
The history and challenges of developing insulin
See Peter Kurtzhals, senior vice president of diabetes research at Novo Nordisk explain about the different types of diabetes and medicine and about the challenges of developing a tablet.
- or listen to Chief Science Officer Mads Krogsgaard Thomsen explaining about diabetes and the discovery of insulin. Click here to see the presentations.
ADA, 73rd Scientific Sessions
New sustainability magazine: The TBL Quarterly
14 May - Today, Novo Nordisk publishes the first issue of the digital sustainability magazine: The TBL Quarterly. Read about Novo Nordisk's initiatives in Vietnam, Malaysia and Indonesia; from prevention to educating healthcare professionals on how to diagnose and treat diabetes.
Read more and download pdf-version or app of the new magazine.
Team Novo Nordisk racing
8 March - Team Novo Nordisk is a global sports team with more than 100 cyclists, triathletes and runners who all have diabetes, spearheaded by the professional cycling team. The team’s mission is to educate, empower and inspire those affected by diabetes. Supporters can follow the team at www.facebook.com/TeamNovoNordisk and www.twitter.com/TeamNovoNordisk. Read more, see the video and get images